Talaris Therapeutics (TALS) IPO Opens Modestly Higher

Today's IPO for Talaris Therapeutics (NASDAQ: TALS) opened for trading at $17.25 after pricing 8,825,000 shares of common stock at a price to the public of $17.00 per share.

Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky.

You May Also Be Interested In

• Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
• Veg House Holdings (VEG) Announces 1M Share IPO at $5/sh
• Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh